We would love to hear your thoughts about our site and services, please take our survey here.
Bertocchi, I, Foglietta, F, Collotta, D, et al. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing. Br J Pharmacol. 2020; 1– 10. https://doi.org/10.1111/bph.15229
More Tranilast literature...
https://arxiv.org/abs/2008.04172v1
I’m no expert but these are interesting readings related to Tranilast (NXP002). This makes me trust the BOD a bit more because most directors would have communicated any potential COVID-19 connection straight away.
Huang Y et al. (2018).
Tranilast directly targets NLRP3 to treat inflammasome-driven diseases.
https://www.embopress.org/doi/full/10.15252/emmm.201708689
Zheng Wang et al. (2020).
NLRP3 Inflammasome and Inflammatory Diseases
https://www.hindawi.com/journals/omcl/2020/4063562/
Nabirotchkin, Serguei & Peluffo, Alex &
Bouaziz, Jan & Cohen, Daniel. (2020).
Focusing on the Unfolded Protein Response and Autophagy Related Pathways to Reposition Common Approved Drugs against COVID-19
https://www.preprints.org/manuscript/202003.0302/v1/download
Interesting, it seems there is also a trial with tranilast which is NXP002.
Sorry if this has already been shared, I have not followed the markets and forums recently to avoid temptation to sell all my portfolio and run away.
http://www.chictr.org.cn/showprojen.aspx?proj=49738
I think it’s a good incentive, he’s committing to work for free unless the SP goes up from yesterday’s SP!
“The Warrants are exercisable from 17 February 2021 to 17 February 2023, at an exercise price of 6.75 pence per ordinary share.“
This might have been covered before but I thought I would share my research on the tranilast patents (NXP002). Dan mentioned in some of his interviews that there have already been studies of inhaled tranilast delivery.
Kissei filled the patent below for “Easily dissolvable powder inhalant composed of tranilast” years ago.
https://patents.google.com/patent/JP2011093849A/en
In Nuformix’s patent below there is a comparison between NFX tranilast cocrystals and the pure tranilast crystalline form.
https://patents.google.com/patent/WO2013144916A1/en
“[0170] For poorly soluble drugs, such as tranilast, the rate of dissolution of the drug form used can have an impact on the overall absorption and thus bioavailability of the drug, especially for example, in the case of oral solid dosage or inhalation delivery methods.”
“It can be seen from this graph that all of the cocrystals demonstrate accelerated dissolution behaviour in this media compared to crystalline traniiast. Most of the cocrystals reach almost their maximum dissolution within the first minute. In particular the 1:1 traniiast nicotinamide cocrysta! shows almost complete dissolution within 1 minute whereas the crystalline tranilast is only about 5% dissolved after this time.”
IMHO this shows that a collaboration would make complete sense for both companies.
NFX might have also seen some data that has led them to proceed with the inhaled delivery but this is just speculation with no evidence.
Completely agree, I think he did very well and reinforced my confidence. He also got rid of traders who kept complaining about lack of news by giving them what they wanted. It’s amazing the timelines those people had in mind, we have been told lots of news within 3 months and people have sold, 3 months!!
Thanks Dave, good read. Dan also mentioned that in this interview.
https://www.cambridgeindependent.co.uk/news/cannabis-benefits-mount-up-for-cambridge-science-9074755/
Hi Soupdragon, I do my research but I accept I will not have all the details the board had. I wish I had all the information and I find your research very helpful. I only think it is unfair to demand all those details to be public. The lack of information is part of the risk of the investment so it affects the valuation of the company but these details will get unravelled in the long term. The board seems competent and trustworthy based on previous results and that makes me confortable but I could be wrong since this is just my guess.
Fully agree with whimax and cdub. There is no need to disclose all of that information, our partners could have many reasons to keep that private especially if they are investing in a controversial sector. Our BOD would have checked all those details as part of the due diligence for that kind of deal. They will also be backed by contracts protecting the IP in case of contract breach or default.
I’m really surprised with some comments in the last couple of days. The SP is 4x where it was a year ago and people are questioning the BOD? Not sure what other product can offer that type of return and still have the potential to continue growing. It is obvious most people have never worked in a corporate environment where deals, due diligence and bureaucracy take a long time and have never delegated as they need to micromanage the BOD... also they argue they have the right to do it as shareholders when the vast majority of holders are happy with (or part of) the BOD.
Indeed.
One of them was already mentioned in the Ebers update RNS on 9th Sep.
“About the Cannabinoid Product Market
The cannabinoid product market is perceived to be a rapidly growing and significant market in products not containing THC. The projected US cannabinoid-based pharmaceuticals market alone is expected to grow ~US$ 50bn by 2029 1. The existing wider cannabinoid product market is large and growing. Global CBD product sales are estimated at £1.1bn in 2018 and forecast to reach £22bn by 2025 2, with GW Pharma's Epidiolex, a CBD-based pharmaceutical product, forecast to achieve annual sales of £1.7bn 3. Through the agreement with Ebers Tech, Nuformix will benefit from adding its technology to a range of products into multiple markets versus taking a single product containing our technology into a single market.”
Dave, I think that paragraph also refers to NXP002 as described in the patent below and in this old NFX presentation.
“Tranilast is currently marketed in Japan and South Korea by Kissei Pharmaceutical Co. Ltd under the Rizaben® brand name. As well as displaying an anti-allergic effect tranilast has been shown to possess anti-proliferative properties. Tranilast was found to inhibit the proliferation of fibroblasts and suppress collagen synthesis (M. Isaji. Biochem Pharmacol. 1987; 36: 469-474) and also to inhibit the transformation of fibroblasts to myofibroblasts and their subsequent contraction (M. Isaji. Life Sci. 1994; 55: 287-292)”
http://www.freepatentsonline.com/y2018/0118662.html
“The current marketed drug form cannot exploit it’s vast anti-fibrotic potential” page 18
https://nuformix.com/app/uploads/2017/10/Nuformix-Investor-Summary-.pdf
Hi Phen, if the terms on the article are true (“annual royalty payments worth more than £200 million.”) that means Nuformix has already secured becoming a unicorn if 002 is successful and gas got the funding for the tests. Any other future deal or product will only add to that so I don’t think it’s a bad deal in the long term.
I think the date in that article is somehow wrong, I believe that relates to his appointment back in 2015. The current CPI FD is Tracey Stonehouse who took over when Kirk left in 2018.
https://www.uk-cpi.com/about/people
I guess those attending the AGM will hear more details of the resignation so please share.
It depends on your strategy, I’m invested here so I’m hoping it will go up in the long term.
Hi HunSen, the TR1 is the other way round. They reported they got 3.91% in Jun and today they have reported they have less than 3%, potentially 0% based on the big trades we saw last week. I don’t really know the purpose of their initial acquisition and now disposal... perhaps they were covering for shorts that were opened on their site and have now been closed?